H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Fortress Biotech today and set a price target of $17.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Pantginis has given his Buy rating due to a combination of factors influencing Fortress Biotech’s current and future prospects. The recent developments include a Complete Response Letter (CRL) for Cyprium/Sentynl’s CUTX-101, which, despite being a setback, is primarily related to manufacturing issues that are expected to be resolved. Importantly, the drug’s efficacy and potential approval remain unaffected, and the Rare Pediatric Disease Priority Review Voucher (PRV) is still intact, offering significant financial upside if sold.
Additionally, Fortress Biotech’s subsidiary, Urica Therapeutics, has entered into a lucrative agreement with Crystalys Therapeutics, securing a $205 million Series A Financing. This deal not only provides the necessary funds to complete Phase 3 trials for dotinurad in gout but also grants Urica a 3% royalty on future sales. Fortress Biotech stands to benefit from its majority ownership in Urica, gaining indirect equity in Crystalys and potential future revenue streams, reinforcing the Buy rating.